Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

BioResearch Ireland (BRI) announces anti-Streptokinase and oestradiol tests:

This article was originally published in Clinica

  • News

Executive Summary

BioResearch Ireland (BRI) has developed an assay for anti- streptokinase antibodies and a saliva test for oestradiol 17-beta. The two-hour, latex-agglutination SK test is intended for use in heart attack patients who may have had streptokinase treatment for previous heart attacks or even a streptococcal infection. Anti-SK antibodies can neutralise therapeutic streptokinase. The oestradiol assay is a two-hour direct, competitive, solid phase enzyme immunoassay. Saliva-based testing makes repetitive sampling in fertility diagnosis and treatment much less unpleasant.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

ORA’s Chief Says Without Additional Funding, Inspections Are In Jeopardy

News We’re Watching: Philips Settles Recall Fallout; FDA REdI, Townhalls, Approvals

ICER Debuts Clinical Trial Diversity Assessment Framework

UK MHRA’s Strategic Approach To AI Will Be ‘Proportionate’ And Fit Well Internationally

See All
UsernamePublicRestriction

Register

MT088044

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By